

SUPPORT FOR THE AMENDMENTS

Claims 1-7, 17, 18, 23, and 25 have been canceled.

Claims 8-13, 15-17, 19, 20, 22, 24, and 26 are currently amended.

The amendment to Claims 8, 11, 12, 13, 15-17, 19, 20, 22, 24, and 26 can be found in the corresponding claims as originally filed and pg 27, lines 1-7.

No new matter is believed to have been added by the present amendment.

REMARKS

Claims 8-16, 19-22, 24, and 26 are pending in the present application.

The rejection of Claims 1-3 and 26 under 35 U.S.C. §101, is obviated by amendment. Applicants have amended the claims to address the Examiner's criticism. Withdrawal of this ground of rejection is requested.

The rejection of Claims 13-16 under 35 U.S.C. §112, second paragraph, is obviated by amendment.

Applicants make no statement with respect to the propriety of this ground of rejection and in no way acquiesce to the same. Solely to expedite examination, Applicants have amended the claims to address the Examiner's specific criticism.

Withdrawal of this ground of rejection is requested.

The rejections of: (a) Claims 1-3 and 26 under 35 U.S.C. §102(b) over Call et al (US 2002/0128196) and (b) Claims 1-3, 13-16, and 26 under 35 U.S.C. §102(b) over Moore et al (WO 02/099084), are obviated by amendment.

In the Office Action, the Examiner has rejected the claims as being anticipated by Call (US 2002/0128196) and Moore (WO 02/099084). The Examiner's rejections are based on the interpretation of the claims as not being limited to any specific sequence. Applicants make no statement as to the propriety of these grounds of rejection as they relate to the previously presented scope and reserve the right to present these claims for further consideration in a continuation application. Solely to expedite examination of the elected invention, However, Applicants have amended the claims herein to define the peptide "consisting of" the sequence to SEQ ID NO: 24.


With respect to Call, this reference discloses in SEQ ID NO: 6 what appears to be the full-length human WT1 protein. As for Moore, this reference discloses a WT1 protein fragment (WT1 F1), which includes the sequence of SEQ ID NO: 24. However, neither of these disclosures provide a peptide "consisting of" the sequence of SEQ ID NO: 24. As such, the claimed invention is not anticipated by either Call et al or Moore et al.

Withdrawal of this ground of rejection is requested.

Applicants submit that the present application is in condition for allowance. Early notification to this effect is respectfully requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, L.L.P.
Norman F. Oblon



Vincent K. Shier, Ph.D.
Attorney of Record
Registration No. 50,552

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 08/07)